Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457677 | 0.84 | MAPK1 (0.32) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL1811213 | 0.78 | MAPK1 (0.32) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL11025931 | 0.75 | MAPK1 (0.43) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL8239850 | 0.72 | MAPK1 (0.41) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL18185730 | 0.72 | MAPK1 (0.50) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL15995542 | 0.72 | MAPK1 (0.41) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL19434761 | 0.68 | MAPK1 (0.37) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL16904324 | 0.68 | MAPK1 (0.37) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL19450480 | 0.68 | MAPK1 (0.37) | MAPK1TP53NFKB1CYP2C19THPO | |
| SCHEMBL30148908 | 0.67 | MAPK1 (0.35) | MAPK1TP53NFKB1CYP2C19THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-2496556-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011053948-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-05-05 | — | — | WO | disclosed |
| US-5225207-A | Complexes derived from platinum, their preparation and the pharmaceutical compositions which contain them | LABORATOIRE ROGER BELLON (FR) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | MAPK1 1803/4885TP53 4388/4885NFKB1 3308/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | MAPK1 1803/4885TP53 4388/4885NFKB1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.